Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 213

1.

Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02.

Wen PY, Chang SM, Lamborn KR, Kuhn JG, Norden AD, Cloughesy TF, Robins HI, Lieberman FS, Gilbert MR, Mehta MP, Drappatz J, Groves MD, Santagata S, Ligon AH, Yung WK, Wright JJ, Dancey J, Aldape KD, Prados MD, Ligon KL.

Neuro Oncol. 2014 Apr;16(4):567-78. doi: 10.1093/neuonc/not247. Epub 2014 Jan 26.

2.

Challenges relating to solid tumour brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO group.

Lin NU, Lee EQ, Aoyama H, Barani IJ, Baumert BG, Brown PD, Camidge DR, Chang SM, Dancey J, Gaspar LE, Harris GJ, Hodi FS, Kalkanis SN, Lamborn KR, Linskey ME, Macdonald DR, Margolin K, Mehta MP, Schiff D, Soffietti R, Suh JH, van den Bent MJ, Vogelbaum MA, Wefel JS, Wen PY; Response Assessment in Neuro-Oncology (RANO) group.

Lancet Oncol. 2013 Sep;14(10):e396-406. doi: 10.1016/S1470-2045(13)70311-5. Review.

PMID:
23993384
3.

Visual field defects after radiosurgery for mesial temporal lobe epilepsy.

Hensley-Judge H, Quigg M, Barbaro NM, Newman SA, Ward MM, Chang EF, Broshek DK, Lamborn KR, Laxer KD, Garcia P, Heck CN, Kondziolka D, Beach R, Salanova V, Goodman R.

Epilepsia. 2013 Aug;54(8):1376-80. doi: 10.1111/epi.12215. Epub 2013 May 10.

4.

Survival analysis in patients with newly diagnosed glioblastoma using pre- and postradiotherapy MR spectroscopic imaging.

Li Y, Lupo JM, Parvataneni R, Lamborn KR, Cha S, Chang SM, Nelson SJ.

Neuro Oncol. 2013 May;15(5):607-17. doi: 10.1093/neuonc/nos334. Epub 2013 Feb 7.

5.

Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02.

Lee EQ, Kuhn J, Lamborn KR, Abrey L, DeAngelis LM, Lieberman F, Robins HI, Chang SM, Yung WK, Drappatz J, Mehta MP, Levin VA, Aldape K, Dancey JE, Wright JJ, Prados MD, Cloughesy TF, Gilbert MR, Wen PY.

Neuro Oncol. 2012 Dec;14(12):1511-8. doi: 10.1093/neuonc/nos264. Epub 2012 Oct 24.

6.

Phase I study of vorinostat in combination with temozolomide in patients with high-grade gliomas: North American Brain Tumor Consortium Study 04-03.

Lee EQ, Puduvalli VK, Reid JM, Kuhn JG, Lamborn KR, Cloughesy TF, Chang SM, Drappatz J, Yung WK, Gilbert MR, Robins HI, Lieberman FS, Lassman AB, McGovern RM, Xu J, Desideri S, Ye X, Ames MM, Espinoza-Delgado I, Prados MD, Wen PY.

Clin Cancer Res. 2012 Nov 1;18(21):6032-9. doi: 10.1158/1078-0432.CCR-12-1841. Epub 2012 Aug 24.

7.

Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors.

Vivanco I, Robins HI, Rohle D, Campos C, Grommes C, Nghiemphu PL, Kubek S, Oldrini B, Chheda MG, Yannuzzi N, Tao H, Zhu S, Iwanami A, Kuga D, Dang J, Pedraza A, Brennan CW, Heguy A, Liau LM, Lieberman F, Yung WK, Gilbert MR, Reardon DA, Drappatz J, Wen PY, Lamborn KR, Chang SM, Prados MD, Fine HA, Horvath S, Wu N, Lassman AB, DeAngelis LM, Yong WH, Kuhn JG, Mischel PS, Mehta MP, Cloughesy TF, Mellinghoff IK.

Cancer Discov. 2012 May;2(5):458-71. doi: 10.1158/2159-8290.CD-11-0284. Epub 2012 Mar 31.

8.

The superiority of conservative resection and adjuvant radiation for craniopharyngiomas.

Schoenfeld A, Pekmezci M, Barnes MJ, Tihan T, Gupta N, Lamborn KR, Banerjee A, Mueller S, Chang S, Berger MS, Haas-Kogan D.

J Neurooncol. 2012 May;108(1):133-9. doi: 10.1007/s11060-012-0806-7. Epub 2012 Feb 15.

9.

Spatial characteristics of newly diagnosed grade 3 glioma assessed by magnetic resonance metabolic and diffusion tensor imaging.

Ozturk-Isik E, Pirzkall A, Lamborn KR, Cha S, Chang SM, Nelson SJ.

Transl Oncol. 2012 Feb;5(1):10-8. Epub 2012 Feb 1.

10.

Prognostic factors for survival in patients treated with stereotactic radiosurgery for recurrent brain metastases after prior whole brain radiotherapy.

Caballero JA, Sneed PK, Lamborn KR, Ma L, Denduluri S, Nakamura JL, Barani IJ, McDermott MW.

Int J Radiat Oncol Biol Phys. 2012 May 1;83(1):303-9. doi: 10.1016/j.ijrobp.2011.06.1987. Epub 2011 Nov 11.

PMID:
22079723
11.

Conditional probability of survival in patients with newly diagnosed glioblastoma.

Polley MY, Lamborn KR, Chang SM, Butowski N, Clarke JL, Prados M.

J Clin Oncol. 2011 Nov 1;29(31):4175-80. doi: 10.1200/JCO.2010.32.4343. Epub 2011 Oct 3. Erratum in: J Clin Oncol. 2011 Dec 20;29(36):4847.

12.

Phase II and pharmacogenomics study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme and gliosarcoma.

Butowski N, Chang SM, Lamborn KR, Polley MY, Pieper R, Costello JF, Vandenberg S, Parvataneni R, Nicole A, Sneed PK, Clarke J, Hsieh E, Costa BM, Reis RM, Hristova-Kazmierski M, Nicol SJ, Thornton DE, Prados MD.

Neuro Oncol. 2011 Dec;13(12):1331-8. doi: 10.1093/neuonc/nor130. Epub 2011 Sep 6.

13.

Neurosurgical management and prognosis of patients with glioblastoma that progresses during bevacizumab treatment.

Clark AJ, Lamborn KR, Butowski NA, Chang SM, Prados MD, Clarke JL, McDermott MW, Parsa AT, Berger MS, Aghi MK.

Neurosurgery. 2012 Feb;70(2):361-70. doi: 10.1227/NEU.0b013e3182314f9d.

PMID:
21841523
14.

Is surgery at progression a prognostic marker for improved 6-month progression-free survival or overall survival for patients with recurrent glioblastoma?

Clarke JL, Ennis MM, Yung WK, Chang SM, Wen PY, Cloughesy TF, Deangelis LM, Robins HI, Lieberman FS, Fine HA, Abrey L, Gilbert MR, Mehta M, Kuhn JG, Aldape KD, Lamborn KR, Prados MD; North American Brain Tumor Consortium.

Neuro Oncol. 2011 Oct;13(10):1118-24. doi: 10.1093/neuonc/nor110. Epub 2011 Aug 2.

15.

Factors associated with delay to pituitary adenoma diagnosis in patients with visual loss.

Jahangiri A, Lamborn KR, Blevins L, Kunwar S, Aghi MK.

J Neurosurg. 2012 Feb;116(2):283-9. doi: 10.3171/2011.6.JNS101663. Epub 2011 Jul 8.

PMID:
21740118
16.

Cilengitide in patients with recurrent glioblastoma: the results of NABTC 03-02, a phase II trial with measures of treatment delivery.

Gilbert MR, Kuhn J, Lamborn KR, Lieberman F, Wen PY, Mehta M, Cloughesy T, Lassman AB, Deangelis LM, Chang S, Prados M.

J Neurooncol. 2012 Jan;106(1):147-53. doi: 10.1007/s11060-011-0650-1. Epub 2011 Jul 8.

17.

Suprasellar Rathke cleft cysts: clinical presentation and treatment outcomes.

Potts MB, Jahangiri A, Lamborn KR, Blevins LS, Kunwar S, Aghi MK.

Neurosurgery. 2011 Nov;69(5):1058-68; discussion 1068-7. doi: 10.1227/NEU.0b013e318228bcea.

PMID:
21673610
18.

Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study.

de Groot JF, Lamborn KR, Chang SM, Gilbert MR, Cloughesy TF, Aldape K, Yao J, Jackson EF, Lieberman F, Robins HI, Mehta MP, Lassman AB, Deangelis LM, Yung WK, Chen A, Prados MD, Wen PY.

J Clin Oncol. 2011 Jul 1;29(19):2689-95. doi: 10.1200/JCO.2010.34.1636. Epub 2011 May 23.

19.

A phase I/II trial of the histone deacetylase inhibitor romidepsin for adults with recurrent malignant glioma: North American Brain Tumor Consortium Study 03-03.

Iwamoto FM, Lamborn KR, Kuhn JG, Wen PY, Yung WK, Gilbert MR, Chang SM, Lieberman FS, Prados MD, Fine HA.

Neuro Oncol. 2011 May;13(5):509-16. doi: 10.1093/neuonc/nor017. Epub 2011 Mar 3.

20.

Clinical trial end points for high-grade glioma: the evolving landscape.

Reardon DA, Galanis E, DeGroot JF, Cloughesy TF, Wefel JS, Lamborn KR, Lassman AB, Gilbert MR, Sampson JH, Wick W, Chamberlain MC, Macdonald DR, Mehta MP, Vogelbaum MA, Chang SM, Van den Bent MJ, Wen PY.

Neuro Oncol. 2011 Mar;13(3):353-61. doi: 10.1093/neuonc/noq203. Epub 2011 Feb 9. Review.

21.

A phase I trial of tipifarnib with radiation therapy, with and without temozolomide, for patients with newly diagnosed glioblastoma.

Nghiemphu PL, Wen PY, Lamborn KR, Drappatz J, Robins HI, Fink K, Malkin MG, Lieberman FS, DeAngelis LM, Torres-Trejo A, Chang SM, Abrey L, Fine HA, Demopoulos A, Lassman AB, Kesari S, Mehta MP, Prados MD, Cloughesy TF; North American Brain Tumor Consortium.

Int J Radiat Oncol Biol Phys. 2011 Dec 1;81(5):1422-7. doi: 10.1016/j.ijrobp.2010.07.1997. Epub 2010 Oct 8.

22.

Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group.

Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, Degroot J, Wick W, Gilbert MR, Lassman AB, Tsien C, Mikkelsen T, Wong ET, Chamberlain MC, Stupp R, Lamborn KR, Vogelbaum MA, van den Bent MJ, Chang SM.

J Clin Oncol. 2010 Apr 10;28(11):1963-72. doi: 10.1200/JCO.2009.26.3541. Epub 2010 Mar 15.

PMID:
20231676
23.

Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02).

Iwamoto FM, Lamborn KR, Robins HI, Mehta MP, Chang SM, Butowski NA, Deangelis LM, Abrey LE, Zhang WT, Prados MD, Fine HA.

Neuro Oncol. 2010 Aug;12(8):855-61. doi: 10.1093/neuonc/noq025. Epub 2010 Mar 3.

24.

Six-month progression-free survival as an alternative primary efficacy endpoint to overall survival in newly diagnosed glioblastoma patients receiving temozolomide.

Polley MY, Lamborn KR, Chang SM, Butowski N, Clarke JL, Prados M.

Neuro Oncol. 2010 Mar;12(3):274-82. doi: 10.1093/neuonc/nop034. Epub 2009 Dec 21.

25.

Enzastaurin plus temozolomide with radiation therapy in glioblastoma multiforme: a phase I study.

Butowski N, Chang SM, Lamborn KR, Polley MY, Parvataneni R, Hristova-Kazmierski M, Musib L, Nicol SJ, Thornton DE, Prados MD.

Neuro Oncol. 2010 Jun;12(6):608-13. doi: 10.1093/neuonc/nop070. Epub 2010 Feb 15.

26.

Joint NCCTG and NABTC prognostic factors analysis for high-grade recurrent glioma.

Wu W, Lamborn KR, Buckner JC, Novotny PJ, Chang SM, O'Fallon JR, Jaeckle KA, Prados MD.

Neuro Oncol. 2010 Feb;12(2):164-72. doi: 10.1093/neuonc/nop019. Epub 2009 Dec 21.

27.

A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy.

Raizer JJ, Abrey LE, Lassman AB, Chang SM, Lamborn KR, Kuhn JG, Yung WK, Gilbert MR, Aldape KA, Wen PY, Fine HA, Mehta M, Deangelis LM, Lieberman F, Cloughesy TF, Robins HI, Dancey J, Prados MD; North American Brain Tumor Consortium.

Neuro Oncol. 2010 Jan;12(1):95-103. doi: 10.1093/neuonc/nop015. Epub 2009 Dec 14.

28.

A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomas.

Raizer JJ, Abrey LE, Lassman AB, Chang SM, Lamborn KR, Kuhn JG, Yung WK, Gilbert MR, Aldape KD, Wen PY, Fine HA, Mehta M, Deangelis LM, Lieberman F, Cloughesy TF, Robins HI, Dancey J, Prados MD; North American Brain Tumor Consortium.

Neuro Oncol. 2010 Jan;12(1):87-94. doi: 10.1093/neuonc/nop017. Epub 2009 Dec 14.

29.

Multiparametric characterization of grade 2 glioma subtypes using magnetic resonance spectroscopic, perfusion, and diffusion imaging.

Bian W, Khayal IS, Lupo JM, McGue C, Vandenberg S, Lamborn KR, Chang SM, Cha S, Nelson SJ.

Transl Oncol. 2009 Dec;2(4):271-80.

30.

Activation of PI3K/mTOR pathway occurs in most adult low-grade gliomas and predicts patient survival.

McBride SM, Perez DA, Polley MY, Vandenberg SR, Smith JS, Zheng S, Lamborn KR, Wiencke JK, Chang SM, Prados MD, Berger MS, Stokoe D, Haas-Kogan DA.

J Neurooncol. 2010 Mar;97(1):33-40. doi: 10.1007/s11060-009-0004-4. Epub 2009 Aug 25.

31.

Radiation-induced reductions in neurogenesis are ameliorated in mice deficient in CuZnSOD or MnSOD.

Fishman K, Baure J, Zou Y, Huang TT, Andres-Mach M, Rola R, Suarez T, Acharya M, Limoli CL, Lamborn KR, Fike JR.

Free Radic Biol Med. 2009 Nov 15;47(10):1459-67. doi: 10.1016/j.freeradbiomed.2009.08.016. Epub 2009 Aug 22.

32.

Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma.

Norden AD, Raizer JJ, Abrey LE, Lamborn KR, Lassman AB, Chang SM, Yung WK, Gilbert MR, Fine HA, Mehta M, Deangelis LM, Cloughesy TF, Robins HI, Aldape K, Dancey J, Prados MD, Lieberman F, Wen PY.

J Neurooncol. 2010 Jan;96(2):211-7. doi: 10.1007/s11060-009-9948-7. Epub 2009 Jun 28.

33.

Adjuvant enoxaparin therapy may decrease the incidence of postoperative thrombotic events though does not increase the incidence of postoperative intracranial hemorrhage in patients with meningiomas.

Cage TA, Lamborn KR, Ware ML, Frankfurt A, Chakalian L, Berger MS, McDermott MW.

J Neurooncol. 2009 May;93(1):151-6. doi: 10.1007/s11060-009-9886-4. Epub 2009 May 9.

PMID:
19430892
34.

Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08).

Wen PY, Yung WK, Lamborn KR, Norden AD, Cloughesy TF, Abrey LE, Fine HA, Chang SM, Robins HI, Fink K, Deangelis LM, Mehta M, Di Tomaso E, Drappatz J, Kesari S, Ligon KL, Aldape K, Jain RK, Stiles CD, Egorin MJ, Prados MD.

Neuro Oncol. 2009 Dec;11(6):853-60. doi: 10.1215/15228517-2009-010.

35.

A multicenter, prospective pilot study of gamma knife radiosurgery for mesial temporal lobe epilepsy: seizure response, adverse events, and verbal memory.

Barbaro NM, Quigg M, Broshek DK, Ward MM, Lamborn KR, Laxer KD, Larson DA, Dillon W, Verhey L, Garcia P, Steiner L, Heck C, Kondziolka D, Beach R, Olivero W, Witt TC, Salanova V, Goodman R.

Ann Neurol. 2009 Feb;65(2):167-75. doi: 10.1002/ana.21558.

PMID:
19243009
36.

Tumor regrowth between surgery and initiation of adjuvant therapy in patients with newly diagnosed glioblastoma.

Pirzkall A, McGue C, Saraswathy S, Cha S, Liu R, Vandenberg S, Lamborn KR, Berger MS, Chang SM, Nelson SJ.

Neuro Oncol. 2009 Dec;11(6):842-52. doi: 10.1215/15228517-2009-005.

37.

Safety and feasibility of switching from phenytoin to levetiracetam monotherapy for glioma-related seizure control following craniotomy: a randomized phase II pilot study.

Lim DA, Tarapore P, Chang E, Burt M, Chakalian L, Barbaro N, Chang S, Lamborn KR, McDermott MW.

J Neurooncol. 2009 Jul;93(3):349-54. doi: 10.1007/s11060-008-9781-4. Epub 2009 Jan 24.

38.

Prognostic factors and grading systems for overall survival in patients treated with radiosurgery for brain metastases: variation by primary site.

Golden DW, Lamborn KR, McDermott MW, Kunwar S, Wara WM, Nakamura JL, Sneed PK.

J Neurosurg. 2008 Dec;109 Suppl:77-86. doi: 10.3171/JNS/2008/109/12/S13.

PMID:
19123892
39.

Apparent diffusion coefficient and fractional anisotropy of newly diagnosed grade II gliomas.

Khayal IS, McKnight TR, McGue C, Vandenberg S, Lamborn KR, Chang SM, Cha S, Nelson SJ.

NMR Biomed. 2009 May;22(4):449-55. doi: 10.1002/nbm.1357.

40.

Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma.

Prados MD, Chang SM, Butowski N, DeBoer R, Parvataneni R, Carliner H, Kabuubi P, Ayers-Ringler J, Rabbitt J, Page M, Fedoroff A, Sneed PK, Berger MS, McDermott MW, Parsa AT, Vandenberg S, James CD, Lamborn KR, Stokoe D, Haas-Kogan DA.

J Clin Oncol. 2009 Feb 1;27(4):579-84. doi: 10.1200/JCO.2008.18.9639. Epub 2008 Dec 15.

41.

Relationship of pre-surgery metabolic and physiological MR imaging parameters to survival for patients with untreated GBM.

Crawford FW, Khayal IS, McGue C, Saraswathy S, Pirzkall A, Cha S, Lamborn KR, Chang SM, Berger MS, Nelson SJ.

J Neurooncol. 2009 Feb;91(3):337-51. doi: 10.1007/s11060-008-9719-x. Epub 2008 Nov 15.

42.

Preoperative prognostic classification system for hemispheric low-grade gliomas in adults.

Chang EF, Smith JS, Chang SM, Lamborn KR, Prados MD, Butowski N, Barbaro NM, Parsa AT, Berger MS, McDermott MM.

J Neurosurg. 2008 Nov;109(5):817-24. doi: 10.3171/JNS/2008/109/11/0817.

PMID:
18976070
43.

A North American brain tumor consortium phase II study of poly-ICLC for adult patients with recurrent anaplastic gliomas.

Butowski N, Lamborn KR, Lee BL, Prados MD, Cloughesy T, DeAngelis LM, Abrey L, Fink K, Lieberman F, Mehta M, Ian Robins H, Junck L, Salazar AM, Chang SM.

J Neurooncol. 2009 Jan;91(2):183-9. doi: 10.1007/s11060-008-9705-3. Epub 2008 Oct 11.

44.

Evaluation of MR markers that predict survival in patients with newly diagnosed GBM prior to adjuvant therapy.

Saraswathy S, Crawford FW, Lamborn KR, Pirzkall A, Chang S, Cha S, Nelson SJ.

J Neurooncol. 2009 Jan;91(1):69-81. doi: 10.1007/s11060-008-9685-3. Epub 2008 Sep 23.

45.

A phase II clinical trial of poly-ICLC with radiation for adult patients with newly diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05).

Butowski N, Chang SM, Junck L, DeAngelis LM, Abrey L, Fink K, Cloughesy T, Lamborn KR, Salazar AM, Prados MD.

J Neurooncol. 2009 Jan;91(2):175-82. doi: 10.1007/s11060-008-9693-3. Epub 2008 Sep 17.

46.

Signal transduction molecules in gliomas of all grades.

Ermoian RP, Kaprealian T, Lamborn KR, Yang X, Jelluma N, Arvold ND, Zeidman R, Berger MS, Stokoe D, Haas-Kogan DA.

J Neurooncol. 2009 Jan;91(1):19-26. doi: 10.1007/s11060-008-9683-5. Epub 2008 Sep 1.

47.

In reference to lamborn et Al. (Neuro-oncology. 2008;10:162-170).

Meyers CA, Lamborn KR, Prados MD.

Neuro Oncol. 2008 Dec;10(6):1171-2. doi: 10.1215/15228517-2008-055. Epub 2008 Aug 25. No abstract available.

48.

Quality of life in low-grade glioma patients receiving temozolomide.

Liu R, Solheim K, Polley MY, Lamborn KR, Page M, Fedoroff A, Rabbitt J, Butowski N, Prados M, Chang SM.

Neuro Oncol. 2009 Feb;11(1):59-68. doi: 10.1215/15228517-2008-063. Epub 2008 Aug 19.

49.

Neurooncology clinical trial design for targeted therapies: lessons learned from the North American Brain Tumor Consortium.

Chang SM, Lamborn KR, Kuhn JG, Yung WK, Gilbert MR, Wen PY, Fine HA, Mehta MP, DeAngelis LM, Lieberman FS, Cloughesy TF, Robins HI, Abrey LE, Prados MD; North American Brain Tumor Consortium.

Neuro Oncol. 2008 Aug;10(4):631-42. doi: 10.1215/15228517-2008-021. Epub 2008 Jun 17. Review.

50.

Hippocampal neurogenesis and neuroinflammation after cranial irradiation with (56)Fe particles.

Rola R, Fishman K, Baure J, Rosi S, Lamborn KR, Obenaus A, Nelson GA, Fike JR.

Radiat Res. 2008 Jun;169(6):626-32. doi: 10.1667/RR1263.1.

Supplemental Content

Loading ...
Support Center